---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000007"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:38:27.867598+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Immunic appoints Nash as CEO of Gliomic subsidiary; updates Vitt's employment terms

## Summary
- Duane Nash to serve as CEO and President of wholly-owned Gliomic Therapeutics effective Jan 1, 2026, with monthly salary of $33,987.
- Daniel Vitt enters new employment agreement: $305,000 annual salary, 55% target bonus, 50% US working time, $50,000 housing reimbursement.
- Vitt's Suspension Agreement with Immunic AG terminated; he will now devote 50% time to Immunic AG with €282,826.50 annual salary and variable remuneration.
- Nash's prior Executive Chairman agreement expired Dec 31, 2025; he remains Board Chairman but receives no cash retainer during his Gliomic employment term.

## SEC filing metadata
- accession: 0001193805-26-000007
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000007/0001193805-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000007/e665087_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000007
- JSON: https://secwatch.observer/filing/0001193805-26-000007.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.